Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vaccine containing L1 capsid proteins from four types of HPV (ALPHAPAPILLOMAVIRUS), types 6, 11, 16 and 18 that is used to prevent infections from HUMAN PAPILLOMAVIRUSES of these subtypes.
| Descriptor ID |
D000068857
|
| MeSH Number(s) |
D20.215.894.899.498.500
|
| Concept/Terms |
Human Papillomavirus Vaccine L1, Type 6,11,16,18- Human Papillomavirus Vaccine L1, Type 6,11,16,18
- HPV L1 Vaccine, Quadrivalent 6,11,16,18
|
Below are MeSH descriptors whose meaning is more general than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
Below are MeSH descriptors whose meaning is more specific than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
This graph shows the total number of publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in this website by year, and whether "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in Profiles.
-
Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018 12; 6:15-21.
-
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014 Jul 01; 59(1):127-35.